28.91
1.54 (5.63%)
| Previous Close | 27.37 |
| Open | 27.35 |
| Volume | 1,793,836 |
| Avg. Volume (3M) | 1,778,670 |
| Market Cap | 4,760,551,936 |
| Price / Earnings (TTM) | 12.68 |
| Price / Earnings (Forward) | 11.86 |
| Price / Sales | 3.17 |
| Price / Book | 3.60 |
| 52 Weeks Range | |
| Earnings Date | 24 Jul 2024 |
| Profit Margin | 19.15% |
| Operating Margin (TTM) | 27.53% |
| Diluted EPS (TTM) | 2.28 |
| Quarterly Revenue Growth (YOY) | -35.40% |
| Quarterly Earnings Growth (YOY) | -61.50% |
| Total Debt/Equity (MRQ) | 28.66% |
| Current Ratio (MRQ) | 2.99 |
| Operating Cash Flow (TTM) | 374.08 M |
| Levered Free Cash Flow (TTM) | 217.01 M |
| Return on Assets (TTM) | 8.62% |
| Return on Equity (TTM) | 30.08% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Alkermes plc | Bullish | Bullish |
Stockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 0.5 |
| Average | 1.00 |
|
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 1.31% |
| % Held by Institutions | 112.29% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 48.00 (Cantor Fitzgerald, 66.03%) | Buy |
| Median | 37.50 (29.71%) | |
| Low | 32.00 (JP Morgan, 10.69%) | Hold |
| Average | 38.75 (34.04%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 28.13 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 14 Oct 2024 | 37.00 (27.98%) | Hold | 29.05 |
| 25 Jul 2024 | 37.00 (27.98%) | Hold | 28.04 | |
| Cantor Fitzgerald | 10 Oct 2024 | 48.00 (66.03%) | Buy | 27.37 |
| 16 Sep 2024 | 48.00 (66.03%) | Buy | 27.83 | |
| Baird | 25 Jul 2024 | 38.00 (31.44%) | Buy | 28.04 |
| JP Morgan | 25 Jul 2024 | 32.00 (10.69%) | Hold | 28.04 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 17 Oct 2024 | Announcement | Alkermes to Report Third Quarter Financial Results on October 24, 2024 |
| 25 Sep 2024 | Announcement | Alkermes to Host Investor Event to Review Orexin Portfolio Strategy |
| 23 Sep 2024 | Announcement | Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 |
| 19 Sep 2024 | Announcement | Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference |
| 13 Sep 2024 | Announcement | Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program |
| 28 Aug 2024 | Announcement | Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference |
| 22 Aug 2024 | Announcement | Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 |
| 24 Jul 2024 | Announcement | Alkermes plc Reports Second Quarter 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |